Cargando…

HPV Tests Comparison in the Detection and Follow-Up after Surgical Treatment of CIN2+ Lesions

Background: HPV tests differ for technology, targets, and information on genotyping of high risk (HR) HPV. In this study, we evaluated the performance of 6 HPV DNA tests and one mRNA test in the detection of cervical intraepithelial lesions (CIN) and as a test-of-cure in the follow-up after surgical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bottari, Fabio, Iacobone, Anna Daniela, Radice, Davide, Preti, Eleonora Petra, Preti, Mario, Franchi, Dorella, Boveri, Sara, Sandri, Maria Teresa, Passerini, Rita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600734/ https://www.ncbi.nlm.nih.gov/pubmed/36292048 http://dx.doi.org/10.3390/diagnostics12102359

Ejemplares similares

HPV-Testing in Follow-up of Patients Treated for CIN2+ Lesions
por: Mariani, Luciano, et al.
Publicado: (2016)

Human Papillomavirus Same Genotype Persistence and Risk of Cervical Intraepithelial Neoplasia2+ Recurrence
por: Iacobone, Anna Daniela, et al.
Publicado: (2021)

Which Risk Factors and Colposcopic Patterns Are Predictive for High-Grade VAIN? A Retrospective Analysis
por: Iacobone, Anna Daniela, et al.
Publicado: (2023)

Human Papillomavirus Genotype Richness and the Biodiversity of Squamous and Glandular Cervical Dysplasias: A Cross-Sectional Study
por: Gozzini, Elisa, et al.
Publicado: (2023)

Bayesian analysis of baseline risk of CIN2 and ≥CIN3 by HPV genotype in a European referral cohort
por: Bonde, Jesper, et al.
Publicado: (2019)

Human Papillomavirus Genotyping Compared With a Qualitative High-Risk Human Papillomavirus Test After Treatment of High-Grade Cervical Intraepithelial Neoplasia: A Systematic Review
por: Bottari, Fabio, et al.
Publicado: (2019)

Clinical and analytical performance of the BD Onclarity™ HPV assay for detection of CIN2+ lesions on SurePath samples
por: Ejegod, Ditte Møller, et al.
Publicado: (2016)

Fertility-Sparing Treatment for Endometrial Cancer: Oncological and Obstetric Outcomes in Combined Therapies with Levonorgestrel Intrauterine Device
por: Pino, Ida, et al.
Publicado: (2022)

Sparing Is Caring: Hormonal Retreatment in Women with Recurrent Endometrial Cancer after Fertility Preservation Management—A Single Centre Retrospective Study
por: Pino, Ida, et al.
Publicado: (2023)

Vaginosonography versus MRI in Pre-Treatment Evaluation of Early-Stage Cervical Cancer: An Old Tool for a New Precision Approach?
por: Vidal Urbinati, Ailyn M., et al.
Publicado: (2022)

E6/E7 mRNA testing for human papilloma virus-induced high-grade cervical intraepithelial disease (CIN2/CIN3): a promising perspective
por: Origoni, Massimo, et al.
Publicado: (2015)

Performance of HPV DNA testing in the follow-up after treatment of high-grade cervical lesions, adenocarcinoma in situ (AIS) and microinvasive carcinoma
por: Costa, Silvano, et al.
Publicado: (2015)

Tips and Tricks for Early Diagnosis of Cervico-Vaginal Involvement from Extramammary Paget’s Disease of the Vulva: A Referral Center Experience
por: Iacobone, Anna Daniela, et al.
Publicado: (2023)

Progression of CIN1/LSIL HPV Persistent of the Cervix: Actual Progression or CIN3 Coexistence
por: Bruno, Maria Teresa, et al.
Publicado: (2021)

Conservative management of CIN2 p16 positive lesions in women with multiple HPV infection
por: Bruno, Maria Teresa, et al.
Publicado: (2020)

The Role of Photodynamic Therapy in the Treatment of Vulvar Intraepithelial Neoplasia
por: Tosti, Giulio, et al.
Publicado: (2018)

VIN usual type—from the past to the future
por: Preti, Mario, et al.
Publicado: (2015)

Evaluating HPV‐negative CIN2+ in the ATHENA trial
por: Petry, Karl Ulrich, et al.
Publicado: (2016)

The Editorial of the Special Issue “Diagnosis of Lower Genital Tract Disease”
por: Bottari, Fabio, et al.
Publicado: (2023)

Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients
por: Kim, Tae Jin, et al.
Publicado: (2014)

Improving the Quality of Healthcare Provision Regarding HPV Immunization for Women with CIN2+ Lesions: The Experience of the Veneto Region in Italy
por: De Polo, Anna, et al.
Publicado: (2023)

The Role of Methylation of Host and/or Human Papillomavirus (HPV) DNA in Management of Cervical Intraepithelial Neoplasia Grade 2 (CIN2) Lesions
por: Dovnik, Andraž, et al.
Publicado: (2023)

The BD Onclarity HPV Assay on Samples Collected in SurePath Medium Meets the International Guidelines for Human Papillomavirus Test Requirements for Cervical Screening
por: Ejegod, Ditte, et al.
Publicado: (2016)

Efficacy and safety of therapeutic HPV vaccines to treat CIN 2/CIN 3 lesions: a systematic review and meta-analysis of phase II/III clinical trials
por: Ibrahim Khalil, Ahmadaye, et al.
Publicado: (2023)

Up to your NEK2 in CIN
por: Seachrist, Darcie D., et al.
Publicado: (2021)

Effect of Condom Use after CIN Treatment on Cervical HPV Biomarkers Positivity: Prolonged Follow Up Study
por: Valasoulis, George, et al.
Publicado: (2022)

HPV16 variant analysis in primary and recurrent CIN2/3 lesions demonstrates presence of the same consensus variant
por: van der Weele, Pascal, et al.
Publicado: (2019)

HPV DNA testing improves CIN2+ risk stratification and detection of CIN2+ in delayed triage of ASCUS and LSIL. A population-based follow-up study from Western Norway
por: Budal, Elisabeth B, et al.
Publicado: (2014)

Clinical and economic benefit of HPV-load testing in follow-up and management of women postcone biopsy for CIN2–3
por: Almog, B, et al.
Publicado: (2003)

Therapeutic vaccination using HPV 16 E7 to eradicate CIN3
por: Tewari, Krishnansu S.
Publicado: (2019)

Combining HPV DNA load with p16/Ki-67 staining to detect cervical precancerous lesions and predict the progression of CIN1–2 lesions
por: Li, Yuejie, et al.
Publicado: (2019)

CIN2+ detection of the HPV DNA Array genotyping assay in comparison with the Cobas 4800 HPV test and cytology
por: Pesic, Aleksandra, et al.
Publicado: (2019)

Evaluation of BD Onclarity™ HPV Assay on Self-Collected Vaginal and First-Void Urine Samples as Compared to Clinician-Collected Cervical Samples: A Pilot Study
por: Martinelli, Marianna, et al.
Publicado: (2022)

HPV58 E7 Protein Expression Profile in Cervical Cancer and CIN with Immunohistochemistry
por: Zheng, Qiaoli, et al.
Publicado: (2021)

CIN III lesions and regression: retrospective analysis of 635 cases
por: Motamedi, Melodi, et al.
Publicado: (2015)

The wages of CIN
por: Yuen, Karen W., et al.
Publicado: (2008)

CIN grades possessing different HPV RNA location patterns and RNAscope is helpful tool for distinguishing squamous intraepithelial lesions in difficult cervical cases
por: Chen, Ruichao, et al.
Publicado: (2023)

HPV type-specific risks of high-grade CIN during 4 years of follow-up: A population-based prospective study
por: Naucler, P, et al.
Publicado: (2007)

Consistent condom use increases spontaneous regression in high-risk non-HPV16 but not in HPV16 CIN2-3 lesions, a prospective population-based cohort study
por: Munk, Ane Cecilie, et al.
Publicado: (2012)

HPV-positive women with normal cytology remain at increased risk of CIN3 after a negative repeat HPV test
por: Polman, Nicole J, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_42t9c3s5m2fq66u48nfof2uc7u